两名Madrigal首席执行官在公司季度损失和延迟药物试验中出售了24M美元股票。 Two Madrigal execs sold $24M in stock amid company's quarterly loss and delayed drug trial.

2025年12月10日,Madrigal制药公司董事Paul Friedman和Rebecca Taub联合出售43 450股,根据证交会的申报,筹集了大约2 400万美元。 On December 10, 2025, Madrigal Pharmaceuticals directors Paul Friedman and Rebecca Taub sold a combined 43,450 shares, raising about $24 million, according to SEC filings. Friedman出售24,800股,价值552.18美元,股份减少11.7%,Taub出售18,650股,价值552.15美元,股份减少3.89%。 Friedman sold 24,800 shares at $552.18, reducing his stake by 11.7%, while Taub sold 18,650 shares at $552.15, cutting her holding by 3.89%. 据该公司报告,每股季度损失5.08美元,估计数字缺失,其主要药物候选者Resmetirom仍在第三阶段试验中。 The company reported a quarterly loss of $5.08 per share, missing estimates, and its lead drug candidate, resmetirom, remains in Phase 3 trials. 股价为571.44美元,市场上限为12.98亿美元,并获得一致的“购买模式”评级。 The stock closed at $571.44 with a market cap of $12.98 billion and a consensus "Moderate Buy" rating.